A randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia

American Journal of Respiratory and Critical Care Medicine

Volumn 173, Issue 1, 2006, Pages 91-97

  Kollef, Marin ^a   Pittet, Didier ^b   García, Miguel Sánchez ^b   Chastre, Jean ^b   Fagon, Jean Yves ^b   Bonten, Marc ^b   Hyzy, Robert ^b   Fleming, Thomas R ^b   Fuchs, Henry ^b   Bellm, Lisa ^b   Mercat, Alain ^b   Mañez, Rafael ^b   Martínez, Antonio ^b   Eggimann, Philippe ^b   Daguerre, Martín ^b   Luyt, Charles Edouard ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b NONE

Author keywords

Mechanical ventilation; Pneumonia; Prevention

Indexed keywords

ISEGANAN;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEMALE; HUMAN; INTUBATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; VENTILATOR ASSOCIATED PNEUMONIA;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADULT; AGED; ANTI-INFECTIVE AGENTS; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PNEUMONIA; RESPIRATION, ARTIFICIAL; TREATMENT OUTCOME;

EID: 30344462677     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200504-656OC     Document Type: Article

References (29)

1. Hubmayr RD. Statement of the 4th International Consensus Conference in Critical Care on ICU-Acquired Pneumonia. Intensive Care Med 2002;28:1521-1536.
2. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States and the National Nosocomial Infections Surveillance System. Crit Care Med 1999;27:887-892.
3. Heyland DK, Cook DJ, Marshall J, Heule M, Guslits B, Lang J, Jaeschke R. The clinical utility of invasive diagnostic techniques in the setting of ventilator-associated pneumonia. Chest 1999;115:1076-1084.
4. Papazian L, Bregeon F, Thirion X, Gregoire R, Saux P, Denis JP, Perin G, Charrel J, Dumon JF, Affray JP, et al. Effect of ventilator-associated pneumonia on mortality and morbidity. Am J Respir Crit Care Med 1996;154:91-97.
5. Fagon JY, Chastre J, Hance A, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-288.
6. Hugonnet S, Eggimann P, Borst F, Maricot P, Chevrolet JC, Pittet D. Impact of ventilator-associated pneumonia on resource utilization and patient outcome. Infect Control Hosp Epidemiol 2004;25:1090-1096.
7. Gastinne H, Wolff M, Delatour F, Faurisson F, Chevret S. A controlled trial in intensive care units of selective decontamination of the digestive tract with nonabsorbable antibiotics. N Engl J Med 1992;326:594-599.
8. Timsit JF, Chevret S, Valcke J, Misset B, Renaud B, Goldstein FW, Vaury P, Carlet J. Mortality of nosocomial pneumonia in ventilated patients: influence of diagnostic tools. Am J Respir Crit Care Med 1996;154:116-123.
9. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903.
10. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
11. D'Amico R, Pifferi S, Leonetti C, Torri V, Tinazzi A, Liberati A. Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials. BMJ 1998;316:1275-1285.
12. Chen J, Falla TJ, Liu H, Hurst MA, Fujii CA, Mosca DA, Embree JR, Loury DJ, Radel PA, Cheng Chang C, et al. Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues. Biopolymers 2000;55:88-98.
13. Loury D, Embree JR, Steinberg DA, Sonis ST, Fiddes JC. Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;87:544-551.
14. Mosca DA, Hurst MA, So W, Viajar BS, Fujii CA, Falla TJ. IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis. Antimicrob Agents Chemother 2000;44:1803-1808.
15. Giles FJ, Miller CB, Hurd DD, Wingard JR, Fleming TR, Sonis ST, Bradford WZ, Pulliam JG, Anaissie EJ, Beveridge RA, et al. A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). Leuk Lymphoma 2003;44:1165-1172.
16. Giles FJ, Rodriguez R, Weisdorf D, Wingard JR, Martin PJ, Fleming TR, Goldberg SL, Anaissie EJ, Bolwell BJ, Chao NJ, et al. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk Res 2004;28:559-565.
17. Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, Pajak TF, Fleming TR, Henke M, Bourhis J, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 2004;58:674-681.
18. Kollef M, Redman R, Jensen K, Mertens R. A phase IIa safety and microbial kinetic study of iseganan (IB-367) oral solution in intubated patients receiving mechanical ventilation [abstract K1125]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society of Microbiology; 2001. p. 403.
19. Chastre J, Bonten M, Fagon J-Y, Fleming T, Hyzy R, Kollef M, Pittet D, Sanchez Garcia M, for the Prevention of Pneumonia Study. A randomized, double-blind, placebo-controlled, multinational phase III trial of iseganan in prevention of ventilator-associated pneumonia (VAP) [abstract]. Proc Am Thorac Soc 2005;2:A822.
20. Meduri GU, Chastre J. The standardization of bronchoscopic techniques for ventilator-associated pneumonia. Chest 1992;102:557S-564S.
21. Shih WJ, Quan H. Testing for treatment differences with dropouts present in clinical trials: a composite approach. Stat Med 1997;16:1225-1239.
22. Rodriguez-Roldan JM, Altuna-Cuesta A, Lopez A, Carrillo A, Garcia J, Leon J, Martinez-Pellus AJ. Prevention of nosocomial lung infection in ventilated patients: use of an antimicrobial pharyngeal nonabsorbable paste. Crit Care Med 1990;18:1239-1242.
23. Pugin J, Auckenthaler R, Lew DP, Suter PM. Oropharyngeal decontamination decreases incidence of ventilator-associated pneumonia: a randomized, placebo-controlled, double-blind clinical trial. JAMA 1991;265:2704-2710.
24. Abele-Horn M, Dauber A, Bauernfeind A, Russwurm W, Seyfarth-Metzger I, Gleich P, Ruckdeschel G. Decrease in nosocomial pneumonia in ventilated patients by selective oropharyngeal decontamination. Intensive Care Med 1996;23:187-195.
25. Bergmans DC, Bonten MJ, Gaillard CA, Paling JC, van der Geest S, van Tiel FH, Beysens AJ, de Leeuw PW, Stobberingh EE. Prevention of ventilator- associated pneumonia by oral decontamination: a prospective, randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2001;164:382-388.
26. Rocha LA, Martin MJ, Pita S, Paz J, Seco C, Margusino L, Villanueva R, Duran MT. Prevention of nosocomial infection in critically ill patients by selective decontamination of the digestive tract: a randomized, double blind, placebo-controlled study. Intensive Care Med 1992;18:398-404.
27. Korinek AM, Laisne MJ, Nicolas MH, Raskine L, Deroin V, Sanson-Lepors MJ. Selective decontamination of the digestive tract in neurosurgical intensive care unit patients: a double-blind, randomized, placebo-controlled study. Crit Care Med 1993;21:1466-1473.
28. Quinio B, Albanese J, Bues-Charbit M, Viviand X, Martin C. Selective decontamination of the digestive tract in multiple trauma patients: a prospective double-blind, randomized, placebo-controlled study. Chest 1996;109:765-772.
29. Giles FJ, Redman R, Yazji S, Bellm L. Iseganan HCl: a novel antimicrobial agent. Expert Opin Investig Drugs 2002;11:1161-1170.